Well-armed immune cells help long-term nonprogressors contain HIVDecember 05, 2008To help develop an effective HIV vaccine, researchers are trying to better understand how the immune systems of a small minority of HIV-infected people known as long-term non-progressors (LTNPs) contain the virus naturally. CD8+ T cells, which kill cells infected with HIV, enable LTNPs to control HIV, but it has been unclear how CD8+ T cells mediate that control so effectively. A new report shows that the ability to stockpile two molecular weapons makes the HIV-specific CD8+ T cells of LTNPs superior cellular killers. Lead author Stephen Migueles, M.D., senior author Mark Connors, M.D., and colleagues at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, used cutting-edge technology to examine individual CD8+ T cells for their killing prowess. The study included new techniques to measure how many HIV-infected cells each CD8+ T cell destroys, and how rapidly. In laboratory experiments, the scientists found that CD8+ T cells taken from LTNPs efficiently killed HIV-infected cells in less than 1 hour. In contrast, the CD8+ T cells of progressors, or individuals who do not contain the virus without antiretroviral therapy, killed HIV-infected cells inefficiently, even when the CD8+ T cells were present in high numbers or came from progressors being successfully treated with antiretroviral therapy. When CD8+ T cells kill HIV-infected cells, a protein, perforin, made by the CD8+ T cells punches holes in the infected cells. Then a second protein, granzyme B, penetrates those holes and causes the cells to die. Previously, the researchers found that HIV-specific CD8+ T cells of progressors, unlike those of LTNPs, make little perforin when they encounter an HIV-infected cell. It remained unclear, however, whether this deficiency explained why HIV-specific CD8+ T cells of progressors are poor killers. The current study demonstrates a direct relationship between the quantity of both perforin and granzyme B that CD8+ T cells accumulate over time and the ability of CD8+ T cells to eliminate HIV-infected cells. This discovery significantly advances the understanding of the cellular mechanisms unique to LTNPs that explain why their immune systems, unlike those of the majority of HIV-infected people, can control HIV without antiretroviral therapy. According to the NIAID scientists, their results also suggest that an HIV vaccine might control virus replication if it could stimulate HIV-specific CD8+ T cells to robustly stock and rapidly deliver perforin and granzyme B to HIV-infected cells. NIH/National Institute of Allergy and Infectious Diseases |
|||||||||||||||||||
| Related Hiv-infected Cells Current Events and Hiv-infected Cells News Articles New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Pitt researchers find candidates for new HIV drugs While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease. 'Shock and kill' research gives new hope for HIV-1 eradication Latent HIV genes can be 'smoked out' of human cells. The so-called 'shock and kill' technique, described in a preclinical study in BioMed Central's open access journal Retrovirology, might represent a new milestone along the way to the discovery of a cure for HIV/AIDS. Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy A research team at the Scripps Research Institute has obtained the first glimpse of a protein that keeps certain substances, including many drugs, out of cells. The protein, called P-glycoprotein or P-gp for short, is one of the main reasons cancer cells are resistant to chemotherapy drugs. Understanding its structure may help scientists design more effective drugs. Results of landmark study of HIV vaccine published in the Lancet Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online today in two papers in The Lancet. These analyses of the Step study are being conducted, presented and published to inform the continued search for an effective HIV vaccine. Novel method to create personalized immunotherapy treatments Argos Therapeutics and Université de Montréal today announced the presentation of new information on Argos'process for developing dendritic cell-based immunotherapies for HIV. Einstein scientists treat cancer as an infectious disease -- with promising results Researchers at the Albert Einstein College of Medicine of Yeshiva University have shown for the first time that cancers can be successfully treated by targeting the viruses that cause them. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines The first genome-wide association study of an infectious disease, conducted by an international group of researchers through the Center for HIV/AIDS Vaccine Immunology (CHAVI), has yielded a new understanding of why some people can suppress virus levels following HIV infection. Interfering RNA silences genes in 'slippery' immune cells A technical advance in laboratory techniques may provide biology researchers broader access to RNA interference, a process of blocking the activity of targeted genes. HIV inserts into human genome using a DNA-associated protein A human DNA-associated protein called LEDGF is the first such molecule found to control the location of HIV integration in human cells. More Hiv-infected Cells Current Events and Hiv-infected Cells News Articles |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||